Serious infections w/ adalimumab. Marketscan MarketScan claims study (1/17-12/20) of ADA Rx in Hidradenitis Supprativa (n 1650) or psoriasis(8699). Risk of SIE & hospitalization greater w/ HS (HR 1.53); esp for sepsis & GU infxn https://t.co/2qa7O2v6fm
Links:
Risk of Serious Infection With Adalimumab in Hidradenitis Suppurativa Compared …
https://buff.ly/VAxX5aQ
20-11-2025
